Epoch Investment Partners Inc. Sells 13,634 Shares of Eli Lilly and Company $LLY

Key Points

• Epoch Investment Partners Inc. reduced its stake in Eli Lilly and Company by 7.4%, now holding 171,054 shares valued at $141.3 million after selling 13,634 shares in Q1.
• Institutional investors control 82.53% of Eli Lilly's stock, with several large firms significantly increasing their stakes during the same quarter.
• Analysts have cut their price targets for Eli Lilly, with Cantor Fitzgerald lowering it from $975 to $825, while maintaining an "overweight" rating on the stock.

Epoch Investment Partners Inc. decreased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 7.4% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 171,054 shares of the company's stock after selling 13,634 shares during the quarter. Epoch Investment Partners Inc.'s holdings in Eli Lilly and Company were worth $141,275,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. WestEnd Advisors LLC raised its position in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares during the last quarter. Citizens National Bank Trust Department raised its position in Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after buying an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. purchased a new position in Eli Lilly and Company in the 1st quarter worth about $40,000. Mascagni Wealth Management Inc. purchased a new position in Eli Lilly and Company in the 4th quarter worth about $43,000. Finally, O Brien Wealth Partners LLC raised its position in Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after buying an additional 12 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY traded up $0.45 during mid-day trading on Friday, reaching $732.41. 2,542,929 shares of the company traded hands, compared to its average volume of 4,163,527. The company's 50 day moving average price is $749.30 and its 200-day moving average price is $787.01. The firm has a market cap of $693.20 billion, a PE ratio of 47.87, a PEG ratio of 1.02 and a beta of 0.44. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $969.65.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm's revenue was up 37.6% on a year-over-year basis. During the same period in the previous year, the company posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is 39.22%.

Insider Activity at Eli Lilly and Company

In related news, EVP Daniel Skovronsky acquired 1,000 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. The trade was a 0.73% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gabrielle Sulzberger acquired 117 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the purchase, the director owned 2,703 shares in the company, valued at $1,733,109.54. This trade represents a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 4,514 shares of company stock worth $2,894,841 in the last quarter. 0.13% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Cantor Fitzgerald decreased their target price on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a research report on Wednesday, August 13th. Wall Street Zen upgraded Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research note on Friday, August 22nd. HSBC upgraded Eli Lilly and Company from a "reduce" rating to a "hold" rating and boosted their price target for the company from $675.00 to $700.00 in a research note on Wednesday. Leerink Partners restated a "market perform" rating and set a $715.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Finally, Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and an average target price of $950.17.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.